Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Adverum Biotechnologies (NASDAQ:ADVM) announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies (NASDAQ:ADVM) announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Laurent Fischer, MD, President and CEO, along with Szilárd Kiss, MD, Distinguished Professor of Ophthalmology and Board Member, will engage in a fireside chat on August 13, 2025, at 9:00 AM EDT.
The presentation will be accessible via live webcast through Adverum's website investor section, with a replay available for at least 30 days after the event.
Details
News Market Reaction – ADVM
On Aug 7, the first trading day after this news, ADVM closed 2.78% below the previous close.
Data tracked by StockTitan Argus for the Aug 7 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT.
A live webcast of the fireside chat can be accessed in the Investors section of Adverum’s website at www.adverum.com. An archived replay of the webcast will be available for at least 30 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Corporate and Investor Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
Media:
Jason Awe, Ph.D.
Executive Director, Corporate Communications
Email: jawe@adverum.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.